Core Insights - Turn Therapeutics Inc. has appointed Andrew Scott as Vice President of Corporate Communications to enhance investor relations and capital markets strategy as the company enters a new growth phase following its public listing [2][3] Company Overview - Turn Therapeutics is a biotechnology company focused on developing and commercializing products for dermatology, wound care, and infectious diseases [3] - The company has received three FDA clearances for its proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis [3] - Turn Therapeutics is also pursuing global health initiatives in thermostable vaccine delivery aimed at underserved areas worldwide, reflecting its commitment to public health innovation [3] Leadership Background - Andrew Scott brings over 30 years of experience in capital markets and corporate finance, having previously served as Managing Director of Investment Banking at ThinkEquity LLC and Vice President of Business Development at Fortress Biosciences, Inc. [2] - Throughout his career, Mr. Scott has helped raise approximately $3 billion across various transactions within the life sciences sector [2]
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications